These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 37422014)

  • 21. Efficacy of human papillomavirus vaccines: a systematic quantitative review.
    Medeiros LR; Rosa DD; da Rosa MI; Bozzetti MC; Zanini RR
    Int J Gynecol Cancer; 2009 Oct; 19(7):1166-76. PubMed ID: 19823051
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized, observer-blinded immunogenicity trial of Cervarix(®) and Gardasil(®) Human Papillomavirus vaccines in 12-15 year old girls.
    Draper E; Bissett SL; Howell-Jones R; Waight P; Soldan K; Jit M; Andrews N; Miller E; Beddows S
    PLoS One; 2013; 8(5):e61825. PubMed ID: 23650505
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quadrivalent human papillomavirus recombinant vaccine: the first vaccine for cervical cancers.
    Sharma R; Sharma CL
    J Cancer Res Ther; 2007; 3(2):92-5. PubMed ID: 17998730
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Vaccination against human papillomavirus. Implementation and efficacy against cervical cancer control].
    Bégué P; Henrion R; Blanc B; Girard M; Sancho-Garnier H
    Bull Acad Natl Med; 2007 Dec; 191(9):1805-16; discussion 1816-7. PubMed ID: 18663976
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Second-generation prophylactic HPV vaccines: current options and future strategies for vaccines development.
    Fruscalzo A; Londero AP; Bertozzi S; Lellè RJ
    Minerva Med; 2016 Feb; 107(1):26-38. PubMed ID: 26473283
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes.
    Barzon L; Squarzon L; Masiero S; Pacenti M; Marcati G; Mantelli B; Gabrielli L; Pascucci MG; Lazzarotto T; Caputo A; Palù G
    Vaccine; 2014 Sep; 32(41):5357-62. PubMed ID: 25045814
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
    Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
    Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years.
    Einstein MH; Baron M; Levin MJ; Chatterjee A; Fox B; Scholar S; Rosen J; Chakhtoura N; Meric D; Dessy FJ; Datta SK; Descamps D; Dubin G;
    Hum Vaccin; 2011 Dec; 7(12):1343-58. PubMed ID: 22048173
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
    MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined bivalent human papillomavirus vaccine and Candida antigen versus Candida antigen alone in the treatment of recalcitrant warts.
    Marei A; Nofal A; Alakad R; Abdel-Hady A
    J Cosmet Dermatol; 2020 Mar; 19(3):758-762. PubMed ID: 31328869
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Diseases caused by human papilloma viruses].
    Zollner U; Schwarz TF
    Dtsch Med Wochenschr; 2011 May; 136(20):1067-72. PubMed ID: 21560109
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The quadrivalent human papillomavirus vaccine: potential factors in effectiveness.
    Zonfrillo NJ; Hackley B
    J Midwifery Womens Health; 2008; 53(3):188-194. PubMed ID: 18455092
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Durability of the neutralizing antibody response to vaccine and non-vaccine HPV types 7 years following immunization with either Cervarix® or Gardasil® vaccine.
    Godi A; Panwar K; Haque M; Cocuzza CE; Andrews N; Southern J; Turner P; Miller E; Beddows S
    Vaccine; 2019 Apr; 37(18):2455-2462. PubMed ID: 30926298
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevention of cervical cancer: journey to develop the first human papillomavirus virus-like particle vaccine and the next generation vaccine.
    Bryan JT; Buckland B; Hammond J; Jansen KU
    Curr Opin Chem Biol; 2016 Jun; 32():34-47. PubMed ID: 26994695
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results.
    Schiller JT; Castellsagué X; Villa LL; Hildesheim A
    Vaccine; 2008 Aug; 26 Suppl 10(Suppl 10):K53-61. PubMed ID: 18847557
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quadrivalent human papillomavirus (HPV) types 6, 11, 16, 18 vaccine: for the prevention of genital warts in males.
    Garnock-Jones KP; Giuliano AR
    Drugs; 2011 Mar; 71(5):591-602. PubMed ID: 21443282
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Three cases of recalcitrant cutaneous warts treated with quadrivalent human papillomavirus (HPV) vaccine: the HPV type may not determine the outcome.
    Hayashi A; Matsumoto K; Mitsuishi T
    Br J Dermatol; 2020 May; 182(5):1285-1287. PubMed ID: 31675436
    [No Abstract]   [Full Text] [Related]  

  • 38. FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP).
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2010 May; 59(20):626-9. PubMed ID: 20508593
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Protection against uterine cervical cancer by HPV vaccines].
    Inoue M
    Uirusu; 2008 Dec; 58(2):155-63. PubMed ID: 19374193
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil).
    Siddiqui MA; Perry CM
    Drugs; 2006; 66(9):1263-71; discussion 1272-3. PubMed ID: 16827602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.